Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. Issue 2 (7th January 2021)

• Record Type: Journal Article
• Authors: Zhu, Qian‐Ying; Zhao, Ge‐Xin; Li, Yan; Talakatta, Girish; Mai, Hai‐Qiang; Le, Quynh‐Thu; Young, Lawrence S.; Zeng, Mu‐Sheng
• Is Part Of: MedComm. Volume 2:Issue 2(2021)
• Page Start: 175
• Page End: 206
• Publication Date: 2021-01-07
• Subjects: Epstein‐Barr virus -- nasopharyngeal carcinoma -- precision medicine -- signal transduction; 610
• DOI: 10.1002/mco2.32
• Languages: English
• ISSNs: 2688-2663

Abstract

Abstract: Nasopharyngeal carcinoma (NPC) is a squamous carcinoma with apparent geographical and racial distribution, mostly prevalent in East and Southeast Asia, particularly concentrated in southern China. The epidemiological trend over the past decades has suggested a substantial reduction in the incidence rate and mortality rate due to NPC. These results may reflect changes in lifestyle and environment, and more importantly, a deeper comprehension of the pathogenic mechanism of NPC, leading to much progress in the preventing, screening, and treating for this cancer. Herein, we present the recent advances on the key signal pathways involved in pathogenesis of NPC, the mechanism of Epstein‐Barr virus (EBV) entry into the cell, and the progress of EBV vaccine and screening biomarkers. We will also discuss in depth the development of various therapeutic approaches including radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy. These research advancements have led to a new era of precision medicine in NPC. Abstract : Advances on the key signal pathways involved in pathogenesis of nasopharyngeal carcinoma (NPC), the mechanism of Epstein‐Barr virus (EBV) entry into the cell, the progress of EBV vaccine and screening biomarkers, and the development of therapeutic approaches were presented.